MX363118B - Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). - Google Patents

Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).

Info

Publication number
MX363118B
MX363118B MX2014012945A MX2014012945A MX363118B MX 363118 B MX363118 B MX 363118B MX 2014012945 A MX2014012945 A MX 2014012945A MX 2014012945 A MX2014012945 A MX 2014012945A MX 363118 B MX363118 B MX 363118B
Authority
MX
Mexico
Prior art keywords
aminopyrimidine derivatives
lrrk2
pyrazole
modulators
lrrk2 modulators
Prior art date
Application number
MX2014012945A
Other languages
English (en)
Other versions
MX2014012945A (es
Inventor
Chen Huifen
Baker-Glenn Charles
Chambers Mark
K Chan Bryan
Estrada Anthony
Jon Burdick Daniel
Kevin Sweeney Zachary
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2014012945A publication Critical patent/MX2014012945A/es
Publication of MX363118B publication Critical patent/MX363118B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La presente invención se relaciona con compuestos de pirazol que son moduladores de LRRK2, con métodos para elaborar los compuestos, y con métodos para usar los compuestos para el tratamiento de enfermedades asociadas con el receptor LRRK2, tal como la enfermedad de Parkinson.
MX2014012945A 2012-05-03 2013-04-30 Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). MX363118B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642019P 2012-05-03 2012-05-03
PCT/EP2013/058939 WO2013164321A1 (en) 2012-05-03 2013-04-30 Pyrazole aminopyrimidine derivatives as lrrk2 modulators

Publications (2)

Publication Number Publication Date
MX2014012945A MX2014012945A (es) 2015-02-10
MX363118B true MX363118B (es) 2019-03-11

Family

ID=48325675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012945A MX363118B (es) 2012-05-03 2013-04-30 Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).

Country Status (11)

Country Link
US (1) US9212173B2 (es)
EP (1) EP2844652B1 (es)
JP (1) JP6218808B2 (es)
KR (1) KR102091894B1 (es)
CN (2) CN104271569B (es)
BR (1) BR112014026952B1 (es)
CA (1) CA2870049C (es)
HK (1) HK1200820A1 (es)
MX (1) MX363118B (es)
RU (1) RU2637947C2 (es)
WO (1) WO2013164321A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871375C (en) * 2012-05-03 2020-10-27 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
WO2014001973A1 (en) 2012-06-29 2014-01-03 Pfizer Inc. NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
JP6483707B2 (ja) 2013-12-20 2019-03-13 シグナル ファーマシューティカルズ，エルエルシー 置換されたジアミノピリミジル化合物、それらの組成物、及びそれらによる治療方法
RU2016134751A (ru) 2014-01-29 2018-03-02 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения
SG11201605342UA (en) 2014-01-29 2016-08-30 Glaxosmithkline Ip Dev Ltd Compounds
US20170226081A1 (en) * 2014-07-24 2017-08-10 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
EP3350178B1 (en) 2015-09-14 2021-10-20 Pfizer Inc. Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors
WO2017087905A1 (en) * 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
EP3389663A4 (en) 2015-12-16 2019-07-03 Southern Research Institute PYRROLOPYRIMIDINE COMPOUNDS, USE AS LACKERS OF THE LRRK2 KINASE AND METHOD FOR THE PRODUCTION THEREOF
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
CA3025672A1 (en) 2016-06-16 2017-12-21 Denali Therapeutics Inc. Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
CN106588884B (zh) * 2016-11-10 2019-04-09 浙江大学 2-多取代芳环-嘧啶类衍生物及制备和医药用途
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
UA126414C2 (uk) * 2017-11-21 2022-09-28 Деналі Терапьютикс Інк. Поліморфи та тверді форми піримідиніламінопіразолової сполуки та способи їх отримання
JP7284172B2 (ja) * 2017-12-20 2023-05-30 デナリ セラピューティクス インコーポレイテッド ピリミジニル－４－アミノピラゾール化合物の調製方法
JP7364841B2 (ja) * 2018-02-14 2023-10-19 智彦 大和田 酸ハロゲン化物による化合物の製造方法
WO2019159248A1 (ja) 2018-02-14 2019-08-22 大阪有機化学工業株式会社 耐熱性且つ易剥離性の硬化樹脂膜を形成するための硬化性樹脂組成物及びその製造方法
CN113365632B (zh) * 2018-09-25 2024-03-08 卡都瑞恩医药有限公司 氨基嘧啶化合物
WO2020068846A1 (en) * 2018-09-25 2020-04-02 Heterocyclic Compound Heterocyclic compound
CN111718332B (zh) * 2019-03-19 2021-08-17 北京赛特明强医药科技有限公司 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
KR20230091871A (ko) 2020-10-20 2023-06-23 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항제 및 lrrk2 억제제의 병용 요법
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
CN115819405A (zh) * 2022-12-20 2023-03-21 沪渝人工智能研究院 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2422380C (en) * 2000-09-15 2009-03-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
JP5208516B2 (ja) * 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
JP2011513483A (ja) * 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
CA2764983A1 (en) * 2009-06-10 2010-12-16 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
PT2576541T (pt) * 2010-06-04 2016-07-08 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
CN106220614B (zh) * 2010-09-01 2019-07-16 吉利德康涅狄格有限公司 吡啶酮/吡嗪酮、其制备方法及使用方法
KR101566091B1 (ko) * 2010-11-10 2015-11-04 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
MX2014002208A (es) * 2011-08-25 2014-05-28 Hoffmann La Roche Inhibidores de serina/treonina quinasa.
AR088643A1 (es) * 2011-11-03 2014-06-25 Genentech Inc Compuestos de 8-fluoroftalazin-1(2h)-ona
TWI589569B (zh) * 2012-03-01 2017-07-01 亞雷生物製藥股份有限公司 絲胺酸／酥胺酸激酶抑制劑
ES2791648T3 (es) * 2012-09-26 2020-11-05 Hoffmann La Roche Compuestos de pirazol-4-il-heterociclil-carboxamida con éter cíclico y procedimientos de uso
SG11201509027WA (en) * 2013-05-01 2015-12-30 Hoffmann La Roche Biheteroaryl compounds and uses thereof

Also Published As

Publication number Publication date
MX2014012945A (es) 2015-02-10
JP2015515966A (ja) 2015-06-04
WO2013164321A1 (en) 2013-11-07
RU2637947C2 (ru) 2017-12-08
HK1200820A1 (zh) 2015-08-14
RU2014147381A (ru) 2016-06-27
CN104271569A (zh) 2015-01-07
US9212173B2 (en) 2015-12-15
BR112014026952B1 (pt) 2022-03-15
KR20150016532A (ko) 2015-02-12
KR102091894B1 (ko) 2020-03-20
CA2870049C (en) 2020-12-29
CN106220615A (zh) 2016-12-14
CN104271569B (zh) 2016-08-24
US20150051238A1 (en) 2015-02-19
CA2870049A1 (en) 2013-11-07
EP2844652B1 (en) 2019-03-13
BR112014026952A8 (pt) 2021-06-15
BR112014026952A2 (pt) 2017-06-27
JP6218808B2 (ja) 2017-10-25
EP2844652A1 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
MX363118B (es) Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MX349556B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
PH12015501955B1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
MX358172B (es) Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson.
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
NZ737399A (en) Ccr2 modulators
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
HK1195309A1 (zh) 作為激酶 調節劑用於治療帕金森病的 -苯基氨基嘧啶衍生物
EA201291220A1 (ru) Производные аминопиримидина в качестве модуляторов lrrk2
SG194718A1 (en) Novel compounds as modulators of protein kinases
MX2015009773A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2015000129A (es) Derivados de pirimidin pirazolilo.
AU2012284088A8 (en) Heterocyclic compounds and uses thereof
PL2785711T3 (pl) Pochodne 2-(fenylo lub piryd-3-ylo)aminopirymidyny jako modulatory kinazy lrrk2 do leczenia choroby parkinsona
MX2014010537A (es) Moduladores de receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dermicas.
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
UA103468C2 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3
MX2016002931A (es) Moduladores del receptor x hepatico (lxr).
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).